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BACKGROUND: T-cell lymphomas (TCLs) are uncommon in the United States. The accurate diagnosis of TCL is challenging and
requires morphologic interpretation, immunophenotyping, and molecular techniques. The authors compared pathologic diagnoses at
referring centers with diagnoses from expert hematopathology review to determine concordance rates and to characterize the use-
fulness of second-opinion pathology review for TCL. METHODS: Patients in the National Comprehensive Cancer Network non-
Hodgkin lymphoma database with peripheral TCL, not otherwise specified (PTCL-NOS), angioimmunoblastic TCL (AITL), and anaplas-
tic lymphoma kinase (ALK)-positive and ALK-negative anaplastic large cell lymphoma (ALCL) were eligible if they had prior tissue
specimens examined at a referring institution. Pathologic concordance was evaluated using available pathology and diagnostic test-
ing reports and provider progress notes. The etiology of discordance and the potential impact on treatment were examined.
RESULTS: Among 131 eligible patients, 57 (44%) had concordant results, totaling 64% of the 89 patients who were referred with a
final diagnosis. Thirty-two patients (24%) had discordant results, representing 36% of those who were referred with a final diagnosis.
The rates of discordance among patients with of PTCL-NOS, AITL, ALK-negative ALCL, and ALK-positive ALCL were 19%, 33%, 34%,
and 6%, respectively. In 14 patients (44% of discordant results), pathologic reclassification could have resulted in a different therapeu-
tic strategy. Forty-two patients (32%) were referred for classification with a provisional diagnosis. CONCLUSIONS: In a large cohort of
patientswith TCLwhowere referred to National Comprehensive Cancer Network centers, the likelihood of a concordant final diagnosis at a re-
ferring institution was low. As current and future therapies target TCL subsets, these data suggest that patients with suspected TCLs would
benefit fromevaluation by an expert hematopathologist.Cancer 2014;120:1993–9.VC 2014 American Cancer Society.
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INTRODUCTION
Peripheral T-cell lymphomas (TCLs) comprise an uncommon group of diseases that were recently updated in the World
Health Organization (WHO) classification of non-Hodgkin lymphomas (NHLs). The accurate diagnosis of TCL is chal-
lenging, requiring morphologic interpretation, immunophenotyping, and molecular techniques. Establishing a precise di-
agnosis in TCL is critical for determining prognosis and has the potential to impact both therapeutic decisions and clinical
trial enrollment.
Although TCLs are generally associated with poor outcomes, the prognosis varies with disease subtype. Patients with
anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) have the most favorable prognosis,1
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although some studies suggest that outcomes in ALCL
depend on age rather than ALK status.2 Most patients
with TCL receive anthracycline-based induction combi-
nation chemotherapy; however, with the exception of
ALK-positive ALCL, relapse rates are high, and a subset of
patients may benefit from consolidation with autologous
hematopoietic stem cell transplantation (HSCT).3-7 In
recent years, several novel therapies, including histone
deacetylase inhibitors,8,9 pralatrexate,10 and the novel
CD30 antibody-drug conjugate, brentuximab vedo-
tin,11,12 have demonstrated significant promise in treating
TCLs. Thus, as new targeted therapies become available,
accurate classification of TCL will be crucial for determin-
ing appropriate candidates for clinical trial enrollment
and treatment.
Despite the use of advanced techniques, prior studies
evaluating the diagnostic accuracy of expert hematopa-
thologists using both older classification systems and the
newer WHO classification for TCLs have produced sub-
optimal rates of agreement with consensus diagnoses. His-
toric studies evaluating expert hematopathologist
agreement rates with consensus panel diagnoses for TCLs
have demonstrated similar diagnostic accuracy, ranging
from 72% for angioimmunoblastic T-cell lymphoma
(AITL) and peripheral TCL-not otherwise specified
(PTCL-NOS) to 85% for ALCLs.13-15 In a series of recent
studies in 1314 patients with peripheral TCL and natural
killer cell=TCL (NKTCL) by the International T-Cell
Lymphoma Project, the agreement rates between the diag-
noses assigned by individual expert hematopathologists
and the consensus diagnoses assigned by panels of expert
hematopathologists were in the 66% to 97% range for
various TCL subtypes. The agreement rates for the more
common TCL histologies—PTCL-NOS, AITL, ALK-
negative ALCL, and ALK-positive ALCL—were 75%,
81%, 74%, and 97%, respectively.1,16,17 In addition, in a
recent study of upfront autologous HSCT for TCL by the
Nordic Lymphoma Group, referral pathology was reana-
lyzed by national reference center pathologists with an
agreement rate of 87%.6 In another study from the
United Kingdom, all lymphomas diagnosed within a hos-
pital network underwent central review by an expert hem-
atopathologist, and the agreement rate also was 87% for
TCLs.18
Although the studies described above suggest that
consensus expert panel hematopathology review of TCLs
is beneficial, convening an expert panel for each case of
suspected TCL is not feasible. Instead, when a community
pathologist is unsure of a diagnosis of TCL, the biopsy
specimen is referred for second-opinion review, often to a
tertiary center. In real-world practice, expert hematopa-
thology review (often with departmental consensus
review) is the standard of care for TCL diagnosis.
Although concordance between community and expert
hematopathology review has been evaluated in B-cell
NHLs,19 little data exist regarding the rates of agreement
between referring diagnoses and expert review for TCLs
in the United States and the potential impact of patho-
logic reclassification on treatment recommendations. We
evaluated the rate of diagnostic concordance between re-
ferring center diagnoses and expert hematopathology
review for 4 subtypes of TCL at 7 tertiary centers in the
National Comprehensive Cancer Network (NCCN).
MATERIALS AND METHODS
The NCCN NHL Outcomes Project is a multicenter,
prospective registry of comprehensive clinical, treatment,
and outcome data for patients with NHL that was estab-
lished on July 1, 2000. Data collection for patients with
TCLs was initiated on April 1, 2007. Seven institutions
contributed patients to this analysis: City of Hope Cancer
Center (Duarte, Calif), Dana-Farber Cancer Institute
(Boston, Mass), Fox Chase Cancer Center (Philadelphia,
Pa), Robert H. Lurie Comprehensive Cancer Center of
Northwestern University (Chicago, Ill), University of
Michigan Cancer Center (Ann Arbor, Mich), The Uni-
versity of Texas MD Anderson Cancer Center (Houston,
Tex), and Roswell Park Cancer Institute (Buffalo, NY).
The institutional review boards at all participating centers
approved the data-collection protocol. When required,
we obtained written informed consent for medical record
review.
All patients with TCL who presented to participat-
ing NCCN centers between April 1, 2007 and June 15,
2012 were eligible for inclusion. Additional inclusion cri-
teria included a documented pathologic review at a refer-
ring center before expert hematopathology review and a
final diagnosis of 1 of the following 4 TCL WHO sub-
types: PTCL-NOS, AITL, ALK-negative ALCL, and
ALK-positive ALCL.20
The pathologic diagnosis from the referring center
was compared with the final WHO diagnosis at the
NCCN center to establish pathologic concordance rates.
Pathologic concordance was defined as the same pathologic
diagnosis at both the referring center and the NCCN cen-
ter, considering all supporting documentation, including
pathology reports, immunohistochemistry (IHC), flow
cytometry, fluorescence in situ hybridization (FISH) and
cytogenetics, T-cell gene rearrangement studies, and physi-
cian progress notes. Review of the records of all patients
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was performed by 3 of the authors (A.F.H, A.C.-T., and
A.S.L.) to determine pathologic concordance.
Pathology results were separated into the following
categories: 1) concordant, with the same referral and
NCCN diagnoses; 2) provisional diagnosis before second-
opinion referral with further workup suggested; and 3)
discordant, with different referral and NCCN diagnoses.
Patients who were referred with a provisional diagnosis to
a non-NCCN tertiary academic referral center or com-
mercial hematopathology service before the NCCN pre-
sentation were placed in the same provisional diagnosis
category as those who had a provisional referral diagnosis
and were referred directly to an NCCN center for diagno-
sis. Patients who had a provisional diagnosis before
second-opinion referral in which an additional biopsy was
necessary at the NCCN center to make a final diagnosis
were included in the provisional diagnosis category.
To characterize the etiology of discordance, reviewers
assigned each patient with pathologically discordant results
to 1 of the following categories: 1) discordant final referral
diagnosis based on the NCCN center’s interpretation of
existing data, or 2) discordant final referral diagnosis based
on additional studies performed at the NCCN center.
Finally, 5 situations were identified in which pathologic
reclassification might influence a patient’s treatment: 1) be-
nign diagnosis changed to TCL, 2) malignancy other than
NHL changed to TCL, 3) B-cell NHL or classical Hodgkin
lymphoma changed to TCL, 4) NKTCL changed to TCL,
and 5) incorrect or undefined ALK status in patients with
ALCL. Patients who had discordant pathologic diagnoses
and met 1 of these criteria were considered as potentially
having experienced a change in treatment based on patho-
logic reclassification.
When reported in the materials reviewed, informa-
tion was collected regarding the type of biopsy performed
(core-needle or excisional biopsy), the materials received
for review by the NCCN center (the number of paraffin-
embedded tissue blocks and=or slides), the number and
type of studies performed at the referring and NCCN cen-
ters (eg the number of immunostains, T-cell receptor
[TCR] gene rearrangement studies), the duration of the pa-
thology review at the referring and NCCN centers, and the
number of pathologists involved with the case review. De-
scriptive statistics were used to estimate concordance rates,
rates of potential treatment difference, and rates of addi-
tional testing among groups and subgroups. Analyses were
performed using the Fisher’s exact test, t test, or Wilcoxon
rank sum test, as appropriate, to evaluate whether the type
of biopsy or the number or type of ancillary testing per-
formed at the referring center was associated with patho-
logic concordance or with the referring center arriving at a
final diagnosis.
RESULTS
In total, 175 patients with TCL were included in the
NCCN NHL database between April 1, 2007 and June
15, 2012. Twenty-four of those patients had a primary
presentation to a NCCN center and, thus, had no refer-
ring pathology and were ineligible for the study. Twenty
patients had incomplete or insufficient data for analysis—
usually unavailable referral pathology reports for compari-
son—and were excluded.
Of 131 eligible patients, 89 were assigned a final di-
agnosis at the referring center (Fig. 1). Fifty-seven patients
(44%) had pathology results that were concordant with
the NCCN center diagnosis, and 32 (24%) had discord-
ant pathology results. Forty-two patients (32%) were
referred for a second opinion with a provisional diagnosis
and with further workup or additional biopsy suggested.
The rates of pathologic discordance among patients with
PTCL-NOS, AITL, ALK-negative ALCL, and ALK-
positive ALCL were 19%, 33%, 34%, and 6%, respec-
tively (Table 1). Among patients who were referred for a
second opinion with a final diagnosis, the overall discord-
ance rate was 36%, and the discordance rates among
patients with PTCL-NOS, AITL, ALK-negative ALCL,
and ALK-positive ALCL were 38%, 50%, 38%, and 7%,
respectively. Table 1 lists the various referring and final
diagnoses assigned to patients who were diagnosed with
TCL at the NCCN centers.
Of the 32 patients with discordant results who were
referred to an NCCN center with a final diagnosis, 15
(47%) were reclassified based on a different interpretation
of the same data or noncontributory additional studies.
Noncontributory additional studies represented either
studies performed at the NCCN center that were not per-
formed originally at the referring center and were negative
or studies that were repeated at the NCCN center that
had been performed originally and merely confirmed pos-
itivity. In the remaining 17 patients (53%) with discord-
ant results, additional studies were performed at the
NCCN center that led to a different diagnosis. Additional
IHC led to a reclassification in 14 patients, a positive
TCR result led to 1 reclassification, an additional biopsy
with repeat TCR testing led to 1 reclassification, and a
negative FISH test for a 9q34 abnormality supported a
reclassification based on morphology from enteropathy-
associated TCL to PTCL-NOS. Of the patients who were
reclassified because of additional IHC analyses, 2 patients
had ALCLs in which ALK staining had not been
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performed at the referring center; 5 patients had chemo-
kine (C-X-C motif) ligand 13 (CXCL13), and=or pro-
grammed cell death 1 (PD-1), and=or cluster of
differentiation 21 (CD21) stains performed that led to a
reclassification to AITL; in 3 patients, B-cell–specific acti-
vator protein=paired box protein Pax-5 (BSAP=PAX5)
stains, usually in concert with repeat CD15, CD30, and
(on 1 occasion) octamer-binding transcription factor 2
(OCT2) and B-cell octamer binding protein 1 (BOB1)
stains led to a reclassification from classic Hodgkin
lymphoma to ALCL. The remaining 4 patients were
reclassified based on IHC for standard T-cell markers or
CD30.
In 14 patients (11% overall, 16% of patients who
were referred with a final diagnosis, and 44% of patients
who had discordant results), pathologic reclassification
may have resulted in a change in treatment. Three patients
who were referred with benign diagnoses were diagnosed
with TCL at an NCCN center and required treatment.
Eight patients were referred with a diagnosis of B-cell
NHL or classic Hodgkin lymphoma and were reclassified
to TCL. One patient who was referred with a diagnosis of
NKTCL was reclassified to TCL. Two patients were diag-
nosed with ALCL without evaluation of ALK status.
In total, 112 patients (86%) had an excisional biopsy
sample from the referring center submitted for NCCN
hematopathology review. In 19 patients (14%), a core-
needle biopsy sample or other type of sample represented
the primary tissue sample referred for NCCN hematopa-
thology review. Among 42 patients who were referred to
an NCCN center with a preliminary diagnosis, 9 had a
core-biopsy sample or other type of sample referred for
review, and 33 had an excisional biopsy sample. Of the 89
patients who were referred with a final diagnosis, 10 were
referred with a core-biopsy sample or other type of sam-
ple, and 79 had an excisional biopsy sample. Of the 10
TABLE 1. Referral and Final NCCN Diagnoses for Patients With T-Cell Lymphoma (n 5 131)
NCCN Diagnosis: No. of Patients
Referral Diagnosis PTCL NOS AITL ALK1 ALCL ALK2 ALCL Total
PTCL-NOS 15 4 0 3 22
AITL 0 11 0 0 11
ALK1 ALCL 0 0 13 0 13
ALK2 ALCL 1 0 0 18 19
ALCL, no ALK status 0 0 0 2 2
Anaplastic T-cell/NK-cell lymphoproliferative neoplasm 0 0 0 1 1
DLBCL 1 1 0 0 2
EMZL 0 1 0 0 1
Classical Hodgkin lymphoma 1 1 0 3 5
EATL 1 0 0 0 1
TCL without WHO designation 4 1 0 1 6
Atypical lymphoid proliferation 1 1 0 0 2
Benign/reactive 0 2 1 0 3
No definitive diagnosis rendered 0 0 0 1 1
Final referring diagnosis 24 22 14 29 89
Provisional referring diagnosis 24 11 4 3 42
Total patients evaluated at NCCN centers 48 33 18 32 131
Discordant cases: No. (%) 9 (19) 11 (33) 1 (6) 11 (34) 32 (24)
Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; ALK, anaplastic lymphoma kinase; ALK2 ALCL,anaplastic lymphoma kinase-negative anaplastic
large cell lymphoma; ALK1 ALCL,anaplastic lymphoma kinase-positive anaplastic large cell lymphoma; DLBCL, diffuse large B-cell lymphoma; EATL,
enteropathy-associated T-cell lymphoma; EMZL, extranodal marginal zone lymphoma;NCCN, National Comprehensive Cancer Center; NK-cell, natural killer
cell; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; TCL T-cell lymphoma; WHO, World Health Organization.
Figure 1. Comparison of referral and NCCN pathology results
in patients with T-cell lymphoma (TCL). NCCN indicates
National Comprehensive Cancer Network.
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patients referred with a final diagnosis from a core-biopsy
sample or other type of sample, there was 1 patient with a
discordant pathologic diagnosis and 9 patients with con-
cordant pathologic diagnoses. Of the patients who were
referred with an excisional biopsy sample and a final diag-
nosis, there were 48 concordant diagnoses and 31 con-
cordant diagnoses. There was no association between
biopsy type and pathologic concordance among the
patients who were referred with a final diagnosis (P5 .18)
or between biopsy type and whether a final diagnosis was
rendered at the referring center (P5 .09).
Additional testing beyond histologic evaluation of
biopsy material was performed at the referring institution
before the second-opinion referral in 95% of all eligible
patients. IHC stains, flow cytometry, TCR gene rear-
rangement testing, and FISH testing (usually for ALK
rearrangement) were performed in 84%, 52%, 36%, and
6% of patients, respectively. Table 2 describes the studies
performed at the referring center in patients who had a
final diagnosis conferred, separated into those with con-
cordant or discordant results. There was no association
between pathologic concordance or discordance and the
number of IHC stains performed (P5 .23) or the type of
study performed: IHC (P5 .66), flow cytometry
(P5 .83), TCR gene rearrangement testing (P5 .5), the
combination of IHC and flow cytometry (P5 .825), or
the combination of IHC and flow cytometry plus TCR
testing (P5 .6).
The median number of paraffin-embedded tissue
blocks and slides received for review at the NCCN centers
was 0 (range, 0-10 blocks) and 19 (range, 0-65 slides),
respectively. The median duration of time spent reviewing
a case at the NCCN center was 5 days (range, 1-34 days).
From the available documentation, in 72% of the NCCN
pathology reviews, a single NCCN hematopathologist
reportedly reviewed the case. In 28% of cases, it was
reported that cases were referred for intradepartmental con-
sultation by at least 1 hematopathologist or were reviewed
at an intradepartmental conference. Comparatively, in
76% of referring center pathology reviews, it was reported
that cases were reviewed by 1 pathologist; and, in 24% of
cases, it was reported that cases were referred for intrade-
partmental consultation by at least 1 pathologist or were
reviewed at an intradepartmental conference. At the
NCCN center, additional IHC stains, flow cytometry,
TCR gene rearrangement testing, and FISH testing were
performed in 53%, 18%, 18%, and 6% of patients, respec-
tively. The median number of IHC stains performed at the
NCCN centers was 2 (range, 0-29 stains) compared with
11 (range, 0-35 stains) performed at the referring centers.
In 31 patients, a median number of 10 IHC stains (range,
1-40 IHC stains) were performed at an institution other
than the referring institution before NCCN referral.
DISCUSSION
Our review of second-opinion pathology in the NCCN
demonstrated a high rate of pathologic discordance for
most TCL subtypes that were included in the current study
with the exception of ALK-positive ALCL. The discord-
ance rates were particularly high for patients who were
assigned a “final” diagnosis at the referring center. Com-
pared with other studies reporting central review of clinical
trial participant specimens or central review of all patients
with lymphoma in a geographic region, the discordance
rates in our study are high.6,18 We also observed that, in
44% of the patients with discordant pathology results, the
pathologic reclassificationmay have impacted treatment.
Unlike a previous study by our group in which we
demonstrated a high rate of pathologic concordance
between referring and NCCN centers for B-cell NHLs,19
the lower rate of agreement between referring and NCCN
centers suggests that community pathology review is not
equivalent to expert hematopathology review of TCLs.
Often, referring pathologists did not assign a specific diag-
nosis according to the WHO classification. There was no
association between the type of biopsy performed or the
number or types of studies performed at the referring cen-
ter and pathologic concordance or discordance. In fact, in
TABLE 2. Number and Type of Studies Performed
at Referring Centers in Patients Referred with a
Final Diagnosis
No. of Patients (%)
Type of Study Performed
at Referring Institution
Concordant
Diagnoses,
n 5 57
Discordant
Diagnoses,
n 5 32
IHC
Yes 54 (95) 29 (91)
No/not mentioned 3 (5) 3 (9)
Flow cytometry
Yes 32 (56) 17 (53)
No/not mentioned 25 (44) 15 (47)
TCR gene rearrangement
Yes 19 (33) 13 (41)
No/not mentioned 38 (67) 19 (59)
FISH
Yes 5 (9) 0 (0)
No/not mentioned 52 (91) 32 (100)
IHC and flow cytometry 31 (54) 16 (50)
IHC, flow cytometry, and TCR 15 (26) 6 (19)
Median no. of referring
IHC stains [range]
14 [0–35] 11 [0–31]
Abbreviations: FISH, fluorescence in situ hybridization; IHC, immunohisto-
chemical staining; TCR, T-cell receptor.
Second-Opinion Pathology Review of TCL/Herrera et al
Cancer July 1, 2014 1997
47% of patients with discordant pathology, NCCN hem-
atopathology review of already available diagnostic testing
resulted in a pathologic reclassification. The other half of
patients were reclassified based on additional testing per-
formed at the NCCN center. The most common addi-
tional testing performed was IHC, including novel stains
like CXCL13 and PD-1 that may not be available in the
community. Common reclassifications included a referral
diagnosis of PTCL-NOS reclassified as AITL or ALK-
negative ALCL and a referral diagnosis of classical Hodg-
kin lymphoma reclassified as ALK-negative ALCL. Nota-
bly, 3 patients who originally were diagnosed with benign
conditions were reclassified with TCL at NCCN centers,
which would have resulted in a major difference in treat-
ment. Two of those patients ultimately were diagnosed
with AITL, an aggressive TCL that is notoriously difficult
to accurately diagnose and to distinguish from nonmalig-
nant lymphoid proliferations. Thus, as new advanced
diagnostic tools, including molecular profiling of TCLs,21
become available to enhance the diagnostic accuracy of
TCLs, patients will require review at centers capable of
performing and interpreting these analyses.
It is noteworthy that several patients were referred
for a second opinion without a final diagnosis from the re-
ferring institution or were referred immediately for a sec-
ond opinion with only a provisional diagnosis. Referring
pathologists frequently recognized atypical lymphoid
populations and, sometimes, lymphoid proliferations sug-
gestive of TCL, but they often referred patients for expert
hematopathology review for final diagnosis and classifica-
tion. The considerable proportion of patients referred
with a provisional diagnosis likely reflects how infre-
quently TCLs are encountered in the community and the
inherently challenging nature of accurately diagnosing
TCLs. The high early referral rate suggests that it may al-
ready be common practice for community pathologists to
refer these complicated cases to a tertiary center.
Our study has limitations. First, the numbers of
patients with each subtype of TCL are small. Second, we
compared community pathology review with expert hem-
atopathology review at a tertiary center. For the purposes
of this analysis, we assumed that the diagnosis rendered by
the NCCN hematopathologist was the “correct diag-
nosis.” Prior studies evaluating expert hematopathology
review against consensus expert panels have demonstrated
diagnostic accuracy rates in the 72% to 97% range for the
lymphoma subtypes included in this study.1,14,16,17
Therefore, there may be an inherent discordance rate in
the expert review that should be considered when inter-
preting the data.
Next, because our study population was entirely
composed of patients who were referred to tertiary cen-
ters for further management and pathologic review, our
population may have been enriched for patients with
complex pathology who were more challenging to accu-
rately diagnose. This may explain the higher discordance
rate in our study relative to studies that evaluated all
patients in a geographical region or all individuals en-
rolled on a specific clinical trial. In addition, in estimat-
ing the impact of pathologic reclassification, we did not
examine the actual therapy received by patients in the
study. Finally, the hematopathologists at NCCN centers
were not blinded to the referring pathology, which may
have influenced their decisions regarding a final patho-
logic diagnosis. Nevertheless, awareness of a previously
assigned diagnosis should have biased the hematopathol-
ogists toward a concordant diagnosis and should not
have altered the high discordance rates demonstrated in
this study.
Establishing a precise diagnosis by differentiating
between different TCL subtypes is important for deter-
mining prognosis and has an impact on both therapeutic
decisions and clinical trial eligibility. Prognosis and
response to standard chemotherapy differs between TCL
subtypes; for instance, ALK-positive ALCL is associated
with higher remission rates and improved survival after
induction chemotherapy.1,6 Because of the poor progno-
sis associated with non-ALK-positive ALCL TCLs, many
of these patients are considered for up-front consolidation
with autologous HSCT. Recent data suggest that there
may be differences in outcomes after autologous HSCT
according to TCL subtype, with increased progression-
free and overall survival among patients who have ALK-
negative ALCL compared with patients who have other
TCL subtypes.6 In addition, several currently available
therapies for relapsed or refractory TCLs have differential
activity across different TCLs, with patients who have
AITL less likely to respond to pralatrexate and exhibiting
longer duration of responses to romidepsin.8-10 Thus,
accurate TCL histologic classification is critical for mak-
ing treatment decisions in these patients and will become
increasingly important as we continue to learn about the
differences in outcomes according to TCL subtype after
HSCT and various therapies. Furthermore, with the evo-
lution of clinical trials examining the activity of novel
agents among TCL subtypes, such as brentuximab vedo-
tin, the anti-CD30 antibody drug conjugate, proper clas-
sification will be important for understanding and
identifying these differential responses. The low rate of
pathologic concordance observed in our study stresses the
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importance of centralized expert hematopathology review
in these trials.
In summary, 36% of patients with TCL who were
referred to NCCN centers for a second opinion with a
final diagnosis were reclassified at the NCCN center.
Approximately 1 in 10 patients with TCL in the NCCN
NHL Outcomes Project database had a pathologic reclas-
sification at the NCCN center that may have had an
impact on their treatment. The NCCN NHL Outcomes
Project database is one of the largest reported TCL series
to date using the WHO classification. Given the fre-
quency of pathologic reclassification for TCLs we
observed, our data support obtaining expert hematopa-
thology review for any patient suspected of having TCL as
well as centralized hematopathology review for TCL clini-
cal trials. Indeed, TCLs are uncommon and are difficult
to diagnose accurately. Thus, as current and future thera-
peutic approaches target subsets of TCLs, accurate diag-
nosis and distinguishing between TCL subtypes promises
to become even more important.
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